Biotech & Bioprocessing

How Will the BIOSECURE Act Reshape U.S.-China Biopharma Partnerships?
Biotech & Bioprocessing How Will the BIOSECURE Act Reshape U.S.-China Biopharma Partnerships?

The proposed BIOSECURE Act stands poised to significantly alter the landscape of U.S.-China biopharma partnerships by addressing national security concerns through restrictive measures. Specifically, the act aims to block certain Chinese biotech equipment and service providers from the U.S. market.

How Can We Optimize Cell Line Development for Next-Gen Biologics?
Biotech & Bioprocessing How Can We Optimize Cell Line Development for Next-Gen Biologics?

Optimizing cell line development (CLD) for next-generation biologics is crucial to meet the rapidly growing demand for novel therapeutic modalities. As the biologics sector evolves, it's imperative to address potential bottlenecks in the development process through strategic enhancements and

Is the CCP Influencing US Biotech Through GenScript?
Biotech & Bioprocessing Is the CCP Influencing US Biotech Through GenScript?

Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.

Surge in Cell Banking Outsourcing Market to Hit $33.12B by 2029
Biotech & Bioprocessing Surge in Cell Banking Outsourcing Market to Hit $33.12B by 2029

The Cell Banking Outsourcing Market is on the brink of a significant upswing, with projections estimating a surge from a robust USD 11.03 billion in 2022 to a staggering USD 33.12 billion by 2029. This exponential growth, driven by an impressive Compound Annual Growth Rate (CAGR) of 17.01%,

Merck to Buy Mirus Bio in $600M Deal to Boost Gene Therapy
Biotech & Bioprocessing Merck to Buy Mirus Bio in $600M Deal to Boost Gene Therapy

In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a

How Will AGC and BioConnection Adapt to New CDMO Trends?
Biotech & Bioprocessing How Will AGC and BioConnection Adapt to New CDMO Trends?

Within the dynamic landscape of the Contract Development and Manufacturing Organization (CDMO) industry, strategic alliances are becoming increasingly crucial. The latest collaboration between Japan's AGC Biologics and the Netherlands-based BioConnection illustrates this point poignantly. They have

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later